File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: The clinical outcome of prostate ductal adenocarcinoma: a multicentre matched cohort comparative study

TitleThe clinical outcome of prostate ductal adenocarcinoma: a multicentre matched cohort comparative study
Authors
Issue Date2019
PublisherWiley-Blackwell Publishing Ltd. The Journal's web site is located at http://www.bjui.org/
Citation
The 23rd Hong Kong Urological Assoication Annual Scientific Meeting, Hong Kong, 4 November 2018. In BJU International, v. 123 n. S1, p. 8-9 How to Cite?
AbstractObjective: Prostate Ductal Adenocarcinoma(PDA) is a rare variant of prostate cancer(PCa). There are conflicting reports regarding its oncological outcome and prognosis. To date, there is no consensus on what is the optimal treatment. Patients and Methods: All patients diagnosed with PDA in three institutions from London(UK), Hong Kong and Kingston(Jamaica) during 2005–2015 were included. Treatment included radical surgery, radical radiotherapy or hormone manipulation. Patients who were diagnosed with >=Gleason8 prostate acinar adenocarcinoma(PAA) served as control groups. Results: Of 9812 patients diagnosed with PCa, 157 (1.8%) had PDA; 958 had PAA. PSA at presentation was lower for PDA. 346 (247‐PAA,99‐PDA) had radical prostatectomy; 314 (295‐PAA,19‐PDA) had radical radiotherapy; 449 (416‐PAA,33‐PDA) had hormone treatment. In surgery group, positive margin were 51%(PDA) vs 54%(PAA), p = 0.13. 57%(PDA) vs 46%(PAA) developed biochemical recurrence. 14%(PDA) vs 5.3%(PAA), p = 0.08 developed distant metastasis and 4.5%(PDA) vs 5.3%(PAA) have died. In radiotherapy group,16%(PDA) vs 22%(PAA) had biochemical recurrence, 16%(PDA) vs 9%(PAA), p = 0.01 developed distant metastasis, 17%(PDA) vs 18%(PAA), p = 0.76 have died. In hormone group, 71%(PDA) vs 47%(PAA) developed metastasis at 32 months; 71%(PDA) vs 45%(PAA) have died. Mean follow‐up for all groups is 71 months. Conclusion: PDA patients had higher risk of metastasis compared to the acinar group regardless of treatment offered. Early adjuvant treatment may be required in prostate ductal cancer.
DescriptionOral Presentation
Persistent Identifierhttp://hdl.handle.net/10722/266484
ISSN
2019 Impact Factor: 4.806
2015 SCImago Journal Rankings: 2.009

 

DC FieldValueLanguage
dc.contributor.authorYuen, SKK-
dc.contributor.authorLam, PW-
dc.contributor.authorElhage, O-
dc.contributor.authorMorrison, B-
dc.contributor.authorTsu, HLJ-
dc.contributor.authorKiberu, Y-
dc.contributor.authorKhan, N-
dc.contributor.authorSuleman, MT-
dc.contributor.authorPersad, R-
dc.contributor.authorChandra, A-
dc.contributor.authorDasgupta, P-
dc.date.accessioned2019-01-18T08:20:34Z-
dc.date.available2019-01-18T08:20:34Z-
dc.date.issued2019-
dc.identifier.citationThe 23rd Hong Kong Urological Assoication Annual Scientific Meeting, Hong Kong, 4 November 2018. In BJU International, v. 123 n. S1, p. 8-9-
dc.identifier.issn1464-4096-
dc.identifier.urihttp://hdl.handle.net/10722/266484-
dc.descriptionOral Presentation-
dc.description.abstractObjective: Prostate Ductal Adenocarcinoma(PDA) is a rare variant of prostate cancer(PCa). There are conflicting reports regarding its oncological outcome and prognosis. To date, there is no consensus on what is the optimal treatment. Patients and Methods: All patients diagnosed with PDA in three institutions from London(UK), Hong Kong and Kingston(Jamaica) during 2005–2015 were included. Treatment included radical surgery, radical radiotherapy or hormone manipulation. Patients who were diagnosed with >=Gleason8 prostate acinar adenocarcinoma(PAA) served as control groups. Results: Of 9812 patients diagnosed with PCa, 157 (1.8%) had PDA; 958 had PAA. PSA at presentation was lower for PDA. 346 (247‐PAA,99‐PDA) had radical prostatectomy; 314 (295‐PAA,19‐PDA) had radical radiotherapy; 449 (416‐PAA,33‐PDA) had hormone treatment. In surgery group, positive margin were 51%(PDA) vs 54%(PAA), p = 0.13. 57%(PDA) vs 46%(PAA) developed biochemical recurrence. 14%(PDA) vs 5.3%(PAA), p = 0.08 developed distant metastasis and 4.5%(PDA) vs 5.3%(PAA) have died. In radiotherapy group,16%(PDA) vs 22%(PAA) had biochemical recurrence, 16%(PDA) vs 9%(PAA), p = 0.01 developed distant metastasis, 17%(PDA) vs 18%(PAA), p = 0.76 have died. In hormone group, 71%(PDA) vs 47%(PAA) developed metastasis at 32 months; 71%(PDA) vs 45%(PAA) have died. Mean follow‐up for all groups is 71 months. Conclusion: PDA patients had higher risk of metastasis compared to the acinar group regardless of treatment offered. Early adjuvant treatment may be required in prostate ductal cancer.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing Ltd. The Journal's web site is located at http://www.bjui.org/-
dc.relation.ispartofBJU International-
dc.rightsPreprint This is the pre-peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Postprint This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.-
dc.titleThe clinical outcome of prostate ductal adenocarcinoma: a multicentre matched cohort comparative study-
dc.typeConference_Paper-
dc.identifier.emailLam, PW: lamwayne@hku.hk-
dc.identifier.emailTsu, HLJ: jamestsu@hku.hk-
dc.identifier.authorityLam, PW=rp02305-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1111/bju.14677-
dc.identifier.hkuros296741-
dc.identifier.volume123-
dc.identifier.issueS1-
dc.identifier.spage8-
dc.identifier.epage9-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats